Korro Bio, Inc.(KRRO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,871 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
KRRO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Korro Bio, Inc. (KRRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRRO at 14.1/100 on a 32-signal composite quality model, placing it at rank #2,871 of 2,962 stocks — the bottom half of the AI-ranked universe. KRRO scores in the top quartile across institutional flow (77.8). Areas of concern include revenue scale (0.8) and profitability (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Korro Bio, Inc. reports net income of $-18.9M, free cash flow of $-17.0M. Top institutional holders of KRRO by reported 13-F value include Lynx1 Capital Management, NEA Management Company, VR Adviser, based on the most recent SEC filings. KRRO trades on the Nasdaq exchange and files with the SEC under CIK 1703647. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Korro Bio, Inc. directly from SEC EDGAR. Korro Bio, Inc.'s 13F Pro composite quality score has ranged between 9 and 26 since 2025, currently 14.1 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-18.9M
Free Cash Flow
Q2 2026
$-17.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+181.5% YoYNet Income
-40.3% YoYOperating Income
-32.6% YoYEPS (Diluted)
-33.2% YoYTotal Assets
-49.8% YoYTotal Debt
Op. Cash Flow
-30.8% YoYFree Cash Flow
-1.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.4M +181.5% | $2.3M | $0.00 | $0.00 -100.0% | $14.1M -62.0% | $37.0M |
| Net Income | $-117.3M -40.3% | $-83.6M -3.0% | $-81.2M -39.9% | $-58.0M +31.5% | $-84.7M -219.4% | $-26.5M |
| Operating Income | $-121.9M -32.6% | $-91.9M -8.7% | $-84.5M -43.3% | $-59.0M +29.8% | $-84.0M -205.0% | $-27.6M |
| EPS (Diluted) | $-12.48 -33.2% | $-9.37 +82.3% | $-53.08 +76.7% | $-227.42 | — | — |
| Total Assets | $113.5M -49.8% | $226.2M +2.1% | $221.7M +82.8% | $121.2M -34.6% | $185.4M -30.0% | $264.7M |
| Total Debt | — | — | — | $10.0M +1100.5% | $833.0K | — |
| Operating Cash Flow | $-78.6M -30.8% | $-60.1M +10.7% | $-67.3M -25.4% | $-53.6M +29.5% | $-76.1M -68.3% | $-45.2M |
| Free Cash Flow | $-79.1M -1.4% | $-78.0M -3.8% | $-75.1M -27.8% | $-58.8M +25.6% | $-79.0M -52.3% | $-51.9M |
Get alerted when KRRO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Korro Bio, Inc. including:
Top Institutional Holders of KRRO
Lynx1 Capital Management LP
$20.3M1,538,296 shNEA Management Company, LLC
$17.1M1,297,893 shVR Adviser, LLC
$13.3M1,009,500 shAtlas Venture Life Science Advisors, LLC
$12.7M962,884 shBALYASNY ASSET MANAGEMENT L.P.
$12.5M951,783 shBlackRock, Inc.
$10.8M817,621 shAffinity Asset Advisors, LLC
$9.3M706,904 shNantahala Capital Management, LLC
$8.7M660,036 shADAGE CAPITAL PARTNERS GP, L.L.C.
$7.1M540,968 shADAR1 Capital Management, LLC
$7.1M540,054 sh
| Fund | Value | Shares |
|---|---|---|
| Lynx1 Capital Management LP | $20.3M | 1,538,296 |
| NEA Management Company, LLC | $17.1M | 1,297,893 |
| VR Adviser, LLC | $13.3M | 1,009,500 |
| Atlas Venture Life Science Advisors, LLC | $12.7M | 962,884 |
| BALYASNY ASSET MANAGEMENT L.P. | $12.5M | 951,783 |
| BlackRock, Inc. | $10.8M | 817,621 |
| Affinity Asset Advisors, LLC | $9.3M | 706,904 |
| Nantahala Capital Management, LLC | $8.7M | 660,036 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $7.1M | 540,968 |
| ADAR1 Capital Management, LLC | $7.1M | 540,054 |
Companies Similar to KRRO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Entrada Therapeutics, Inc.
Zenas BioPharma, Inc.
Xencor Inc
Relay Therapeutics, Inc.
Silence Therapeutics plc
Caribou Biosciences, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KRRO on your watchlist
Track score changes the day Korro Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KRRO a good stock to buy?
13F Pro's AI-powered analysis of Korro Bio, Inc. (KRRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KRRO are available on the KRRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KRRO is classified as a small company.
Which hedge funds own KRRO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KRRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Korro Bio, Inc.'s investment landscape.